Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 12/20 | 0.40 |
| ▸ | EML4 | Q9HC35 | 8/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.39 |
| ▸ | RET | P07949 | 11/20 | 0.39 |
| ▸ | ROS1 | P08922 | 11/20 | 0.39 |
| ▸ | SYK | P43405 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24944979 | 1.00 | FLT3 (0.40) | FLT3EML4ALKRETROS1 | |
| SCHEMBL30206375 | 0.92 | FLT3 (0.38) | FLT3EML4ALKRETROS1 | |
| SCHEMBL24943791 | 0.89 | EML4 (0.48) | FLT3EML4ALKRETROS1 | |
| SCHEMBL30801879 | 0.89 | IKBKE (0.35) | FLT3EML4ALKRETROS1 | |
| SCHEMBL24944188 | 0.89 | IKBKE (0.35) | FLT3EML4ALKRETROS1 | |
| SCHEMBL24944782 | 0.87 | RET (0.49) | FLT3EML4ALKRETROS1 | |
| Formic Acid SCHEMBL30206162 | 0.86 | IKBKE (0.33) | FLT3EML4ALKRETROS1 | |
| SCHEMBL24944378 | 0.86 | EML4 (0.46) | FLT3EML4ALKRETROS1 | |
| SCHEMBL30205565 | 0.85 | EML4 (0.40) | FLT3EML4ALKRETROS1 | |
| SCHEMBL30206167 | 0.85 | EML4 (0.41) | FLT3EML4ALKRETROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | claimed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | claimed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | claimed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | claimed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |